Effect of Thiazides on Bone Mineral Density in Children with Idiopathic Hypercalciuria

Overview

Journal Pediatr Nephrol

Specialties Nephrology
Pediatrics

Date 2011 Aug 30

PMID 21874585

Citations 5

Authors

Victor Garcia-Nieto

Margarita Monge-Zamorano

Montserrat Gonzalez-Garcia

Maria Isabel Luis-Yanes

Affiliations

Soon will be listed here.

Abstract

To determine the effect of thiazide treatment on bone mineral density (BMD) in children with idiopathic hypercalciuria (IH) and osteopenia, we reviewed the case notes of 22 children aged 11.7 ± 2.7 years diagnosed with IH and osteopenia who had received thiazides for 2.4 years. The data on this group were compared with those of 32 IH children with osteopenia aged 11.2 ± 2.7 years who had not received thiazide treatment. By the end of the follow-up period, the z-BMD had improved spontaneously in 23 of the 32 control children (72%) and in 12 of the 22 patients on thiazides (54%). Although treated patients had a higher body mass index (BMI) and a higher BMD following treatment, the differences became statistically negligible when these parameters were expressed as z-BMD or as bone mineral apparent density (BMAD). In contrast, within the control group, there were significant differences in BMAD and z-BMD at the end of the follow-up. Patients who had an improved z-BMD at the end of the treatment also showed an increase in their BMI. Based on these results, we conclude that thiazide treatment does not improve the z-BMD in children with IH. More than half of the children suffering from IH enrolled in our study showed a spontaneous improvement in their z-BMD, which was more evident when the initial BMAD was not low and when their BMI increased during the follow-up period.

Citing Articles

Should pediatric idiopathic hypercalciuria be treated with hypocalciuric agents?.

Penido M, Tavares M World J Nephrol. 2021; 10(4):47-58.

PMID: 34430384 PMC: 8353600. DOI: 10.5527/wjn.v10.i4.47.

Evolution of bone mineral density in patients with idiopathic hypercalciuria: a 20-year longitudinal study.

Perez-Suarez G, Yanes M, de Basoa M, Sanchez Almeida E, Garcia Nieto V Pediatr Nephrol. 2020; 36(3):661-667.

PMID: 32980941 DOI: 10.1007/s00467-020-04754-6.

Response to: A role for thiazide diuretic therapy in preventing bone loss, fracture and nephrolithiasis in individuals with thalassemia and hypercalciuria?.

Dede A, Trovas G, Chronopoulos E, Triantafyllopoulos I, Dontas I, Papaioannou N Osteoporos Int. 2017; 28(5):1761-1762.

PMID: 28194475 DOI: 10.1007/s00198-017-3927-1.

Idiopathic hypercalciuria and bone health.

Ryan L, Ing S Curr Osteoporos Rep. 2012; 10(4):286-95.

PMID: 23054957 DOI: 10.1007/s11914-012-0120-5.

Does thiazide treatment improve bone mineral density in hypercalciuric children?.

Penido M, Tavares M Pediatr Nephrol. 2012; 27(8):1417-8.

PMID: 22527531 DOI: 10.1007/s00467-012-2159-z.

References

Coe F, Kavalach A . Hypercalciuria and hyperuricosuria in patients with calcium nephrolithiasis. N Engl J Med. 1974; 291(25):1344-50. DOI: 10.1056/NEJM197412192912510. View

Jergas M, Breitenseher M, Gluer C, Yu W, Genant H . Estimates of volumetric bone density from projectional measurements improve the discriminatory capability of dual X-ray absorptiometry. J Bone Miner Res. 1995; 10(7):1101-10. DOI: 10.1002/jbmr.5650100715. View

Zerwekh J . Bone disease and hypercalciuria in children. Pediatr Nephrol. 2009; 25(3):395-401. DOI: 10.1007/s00467-009-1338-z. View

Maschio G, Tessitore N, DAngelo A, Fabris A, Pagano F, Tasca A . Prevention of calcium nephrolithiasis with low-dose thiazide, amiloride and allopurinol. Am J Med. 1981; 71(4):623-6. DOI: 10.1016/0002-9343(81)90215-1. View

Lafage-Proust M, Margaillan P, Vergely N, Faure S, Paillet S, Lang F . Weight gain reverses bone turnover and restores circadian variation of bone resorption in anorexic patients. Clin Endocrinol (Oxf). 2000; 52(1):113-21. DOI: 10.1046/j.1365-2265.2000.00879.x. View

LaCroix A, Ott S, Ichikawa L, Scholes D, Barlow W . Low-dose hydrochlorothiazide and preservation of bone mineral density in older adults. A randomized, double-blind, placebo-controlled trial. Ann Intern Med. 2000; 133(7):516-26. DOI: 10.7326/0003-4819-133-7-200010030-00010. View

Reusz G, Dobos M, Tulassay T, MILTENYI M . Hydrochlorothiazide treatment of children with hypercalciuria: effects and side effects. Pediatr Nephrol. 1993; 7(6):699-702. DOI: 10.1007/BF01213325. View

Bolotin H . DXA in vivo BMD methodology: an erroneous and misleading research and clinical gauge of bone mineral status, bone fragility, and bone remodelling. Bone. 2007; 41(1):138-54. DOI: 10.1016/j.bone.2007.02.022. View

Freundlich M, Alonzo E, Bellorin-Font E, Weisinger J . Reduced bone mass in children with idiopathic hypercalciuria and in their asymptomatic mothers. Nephrol Dial Transplant. 2002; 17(8):1396-401. DOI: 10.1093/ndt/17.8.1396. View

10.

Eisner B, Ahn J, Stoller M . Differentiating primary from secondary hyperparathyroidism in stone patients: the "thiazide challenge". J Endourol. 2009; 23(2):191-2. DOI: 10.1089/end.2008.0567. View

11.

Ezzat Y, Hamdy K . The frequency of low bone mineral density and its associated risk factors in patients with inflammatory bowel diseases. Int J Rheum Dis. 2010; 13(3):259-65. DOI: 10.1111/j.1756-185X.2010.01542.x. View

12.

Laroche M, Mazieres B . Beneficial effect of a thiazide diuretic on bone mineral density in male osteoporosis with hypercalciuria. Clin Exp Rheumatol. 1998; 16(1):109-10. View

13.

Lalande A, Roux S, Denne M, Stanley E, Schiavi P, Guez D . Indapamide, a thiazide-like diuretic, decreases bone resorption in vitro. J Bone Miner Res. 2001; 16(2):361-70. DOI: 10.1359/jbmr.2001.16.2.361. View

14.

Hall T, Schaueblin M . Hydrochlorothiazide inhibits osteoclastic bone resorption in vitro. Calcif Tissue Int. 1994; 55(4):266-8. DOI: 10.1007/BF00310404. View

15.

Dvorak M, De Joussineau C, Carter D, Pisitkun T, Knepper M, Gamba G . Thiazide diuretics directly induce osteoblast differentiation and mineralized nodule formation by interacting with a sodium chloride co-transporter in bone. J Am Soc Nephrol. 2007; 18(9):2509-16. PMC: 2216427. DOI: 10.1681/ASN.2007030348. View

16.

Carter D, Bouxsein M, Marcus R . New approaches for interpreting projected bone densitometry data. J Bone Miner Res. 1992; 7(2):137-45. DOI: 10.1002/jbmr.5650070204. View

17.

Leppla D, Browne R, Hill K, Pak C . Effect of amiloride with or without hydrochlorothiazide on urinary calcium and saturation of calcium salts. J Clin Endocrinol Metab. 1983; 57(5):920-4. DOI: 10.1210/jcem-57-5-920. View

18.

Voskaki I, Al Qadreh A, Mengreli C, Sbyrakis S . Effect of hydrochlorothiazide on renal hypercalciuria. Child Nephrol Urol. 1992; 12(1):6-9. View

19.

Reusz G, Dobos M, Vasarhelyi B, Sallay P, Horvath C, Szabo A . Sodium transport and bone mineral density in hypercalciuria with thiazide treatment. Pediatr Nephrol. 1998; 12(1):30-4. DOI: 10.1007/s004670050398. View

20.

Olmer M, Berland Y, Argemi B . Absence of secondary hyperparathyroidism in most patients with renal hypercalciuria. Kidney Int Suppl. 1983; 16:S175-9. View